Needham analyst Gil Blum raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $8 and keeps a Buy rating on the shares. The firm says the FDA’s feedback Taysha’s registrational study design for TSHA-102 in Rett syndrome “checked off a wishlist of features.” The agency is allowing for a filing at the six-month interim and the FDA also granted TSHA-102 breakthrough designation, the analyst tells investors in a research note. Needham views the developments as “derisking” for TSHA-102, putting the program well ahead of NGNE-401.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies price target raised to $10 from $8 at Needham
- Positive Outlook for Taysha Gene Therapies: Buy Rating Affirmed with FDA Support and Breakthrough Designation
- Taysha Gene Therapies Gains FDA Breakthrough Designation
- Taysha Gene Therapies announces FDA BTD to TSHA-102
- Taysha Gene Therapies announces inducement grant under Nasdaq listing rule